High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
about
sameAs
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemiaT-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome.Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsA phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomyPhase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case reportAllogeneic hematopoietic cell transplant for prolymphocytic leukemia.Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA.Cancer immunotherapy in clinical practice -- the past, present, and future.CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).Stem cell transplantation for multiple myeloma.Monoclonal antibodies in the treatment of chronic lymphoid leukemias.Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.Immunotherapy of cancer in 2012.Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapyHigh TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemiaIndications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.Alemtuzumab in CLL and other lymphoid neoplasms.T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosisProlymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.Alemtuzumab in the treatment of chronic lymphocytic lymphoma.Receptor-directed therapy of T-cell leukemias and lymphomas.A case of mucosa-associated lymphoid tissue lymphoma of the gastrointestinal tract showing extensive plasma cell differentiation with prominent Russell bodies.Antibody-based therapy of leukaemia.New drug therapies in peripheral T-cell lymphoma.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).Cutaneous T-cell lymphomas: a review of new discoveries and treatments.A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.Novel treatment avenues for peripheral T-cell lymphomas.Therapeutic options for adult T-cell leukemia/lymphoma.Emerging drugs for T-cell lymphoma.A pediatric case of T-cell prolymphocytic leukemia.Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
P2860
Q28263993-1135EEE2-8521-41C5-8AA2-845BEF2671F6Q33348839-4218B20A-2AA9-4B08-A9E2-C5C1FED66366Q33386506-0B65CAD3-F297-4E41-9073-3ABFC94FA2CFQ33388189-C21F8E68-E3D5-4E39-8359-26B5EC905B87Q33394308-BFF54845-9130-413F-933D-B41004938791Q33417186-BBD4016C-3C3C-46B8-9E8B-3BECE4F34639Q33434322-4242E9EB-00C8-42BA-B164-07126FB15C91Q33592181-ADB4AC65-8498-49E8-A603-C80622AFE118Q33729489-08C87876-55BC-4F3E-9E2E-D34B8CD8C2E3Q33960952-C2FF5E6C-1F36-4D38-9070-AB105AA191F1Q34309399-533051B0-F0FC-4E5C-B2C2-6809727A3FA1Q34734092-3DFE5E45-74E6-419E-B74A-E690B767650EQ35022487-226FF094-4628-42DA-9ECC-85672883B17BQ35061729-88D56E7F-65E0-4BB8-BC50-6AFBC594BD3FQ35080315-C5F69CBC-01AB-4A49-A2D9-D2E712D710EFQ35692626-2E6392C6-5C7B-4AF4-ABDE-28B07BE8EB33Q35752823-C92DB76E-BC60-4977-8B1F-CE48382CB74FQ35847654-665C2823-BC27-41C2-A234-BEBA76A90622Q36243536-15BADCBA-EC89-456C-98E3-1081C744F485Q36349776-E75BCE00-9B29-42D0-89F3-16E922B5C312Q36365590-FE6B5786-8C51-4EA4-8860-D19B371CA090Q36384635-18A0155C-E0F3-476B-AAD1-43039605B21CQ36654926-6D5E407A-ADC3-4EFD-BF7B-023EB793876EQ36659824-6D158C82-A8F8-4A9E-9BF4-70043C24CD64Q36894011-793E4206-53A4-4DE3-BB2D-CA341C48F5BDQ37106689-0B401988-28D1-4C42-8DD1-4178CBDBD7F6Q37134417-41F38EEA-13B4-4E18-9B09-39501A6E5E5EQ37196716-5C04972B-A848-458B-A29B-81726D5BCCA8Q37354671-1F4DFBB6-83DA-4BB9-B052-3D0631F68EF0Q37605247-73898D1C-FB21-4C95-84DB-FD57BC846846Q37854715-1A5A5921-4D08-4F47-8683-3405D092F5C7Q37863688-39609ED5-4CDE-4F5E-A91C-4FCD06458B2DQ37981969-13C36769-8266-4A06-99EF-A2E49C96049BQ38003849-50FF43C0-3E5A-4A0D-9946-EC3B3A06275AQ38045460-6D17B174-8B06-4540-BDFA-28EDFA96B12DQ38128790-D69EB6AA-5092-4785-ACC7-06E7BDB7D576Q38196943-A1AC7EA3-5B40-4476-8461-EBDBA9F20C62Q38270616-23AC0B9B-734D-4615-8BA4-278A9E025AB2Q38598544-0DD9F4B3-12ED-47D8-9589-36FF60C37434Q38889962-7730815A-62B2-4327-8708-933F334521DE
P2860
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
description
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im September 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 15 September 2001)
@en
vedecký článok (publikovaný 2001/09/15)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/09/15)
@nl
наукова стаття, опублікована у вересні 2001
@uk
مقالة علمية (نشرت في 15-9-2001)
@ar
name
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@ast
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@en
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@nl
type
label
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@ast
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@en
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@nl
prefLabel
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@ast
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@en
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@nl
P2093
P356
P1433
P1476
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
@en
P2093
A Parreira
B Nomdedeu
C E Dearden
G E Tjønnfjord
N Ketterer
P304
P356
10.1182/BLOOD.V98.6.1721
P407
P577
2001-09-15T00:00:00Z